Global Pioneering IA Technique Of Direct Cerebral Infusion Of Avastin Into Brain Tumor

The world’s foremost intra-arterial cerebral infusion of the drug Avastin or bevacizumab direct inside the malignant brain tumor was conducted by neurosurgeons at the NewYork-Presbyterian Hospital/Weill Cornell Medical Center. This new-fangled intra-arterial or IA procedure could render the cancer cells exposed to increased dosages of the drug treatment and alongside probably spare the patient commonly experienced side effects of being administered the drug intravenously or all through the body.

The analytical technique known as super selective intra-arterial cerebral Avastin infusion – has shown success when conducted on 5 patients with positive outcomes. The detailed information regarding this foremost case is due to be published in the subsequent edition of Journal of Experimental Therapeutics and Oncology.

The researchers are presently signing up candidates for the Phase I of the study that would examine the safety and permissibility of this novel means of drug release. In case it turns out to be a success, NewYork-Presbyterian/Weill Cornell physicians and researchers consider that this method shows imminent potential to offer a novel and improved treatment for GBM or gliioblastoma multiforme – a prevalent kind of brain cancer that has shown undesirable response to presently offered treatments. Additionally, the authors consider that this procedure could be the harbinger of a novel ground of ‘intercessional neuro-oncology’.

Dr. John A. Boockvar, the co-author and study co-principal investigator (PI) and associate professor of neurological surgery at Weill Cornell Medical College as well as the director of the brain tumor research laboratory in NewYok-Presbyterian Hospital/Weill Cornell Medical Center, explicated that the researchers believed that by the direct infusion of Avastin through the cerebral arteries deep inside the location of the brain tumor could aid in obliterating the cancer cells hidden inside the tumor and adjoining brain tissue.

Dr. Howard Riina, the co-director of interventional neuroradiology at the NewYork-Presbyterian Hospital/Weill Cornell Medical Center and associate professor of neurological surgery, neurology and radiology at Weill Cornell Medical College stated that they were coalescing the newest in drug therapy with a path-breaking delivery method, that had potential of being more effectual as compared to the presently obtainable treatments for brain tumors.

Due to the BBB or blood-brain barrier that thwarts several intravenously administered drugs from infiltrating the blood vessel wall adequately in order to reach into the brain; though whether the present drugs really enter into the brain subsequent to intravenous infusion is still not known with surety.

Dr. Boockvar added that this novel technique could be a means of getting past that obstacle and convey increased drug dosages to the tumor with lesser toxicity to the patient.

For delivering the drug, neurosurgeons directed a hair-fine microcatheter via the blood vessels in the body, through the carotid artery travelling up the neck, and then within the smaller arteries deep inside the brain. On reaching the malignant location, a drug for opening the BBB is injected. Subsequent to the BBB being transitorily opened – a window time span of 5 minutes wherein the Avastin – the chemotherapeutic agent is infused straight into the malignant tumor.

Candidates in the trial would be administered different drug doses for testing what dosage could be better tolerated. Subsequent to this Phase I trial, the researchers intend to soon commence on Phase II trial for testing the method’s efficacy.

Popularity: 11% [?]